Dear All (detailed and wonkish note alert … lots of thinking out loud … get some coffee and settle in!), I wrote previously (link) about
Dear All (long, wonkish note alert!): Today we have a 3-part discussion of cost and value with this summary 3-part message: Developing antibiotics is expensive,
Dear All, And now for a change from our usually scheduled content! As you might expect, major agencies in the US (FDA, BARDA, NIAID) and
Heads-up … numerous changes in the meeting calendar: Lots of new events as well as rescheduling of previously announced events. Dear All, A busy start
Dear All, In case you missed it, the 4th AMR Conference sponsored by BEAM, CARB-X, Novo REPAIR, Wellcome Trust, the UK, and many others (link)
Dear All, WHO’s GLASS Secretariat (Global Antimicrobial Resistance Surveillance System, link) have recently released a standardized method for estimating attributable mortality of antimicrobial resistant bloodstream
(Updated on 8 July 2020) Dear All, Mark your calendars now for a major global AMR initiative that will be announced by live virtual events
Dear All (wonkish alert … the first 3 segments are non-wonkish but the last 2 are in the wonkish zone … titrate your plasma caffeine
Dear All, Sharpen your pencils! The Novo REPAIR Impact Fund has just opened its 2020 call for proposals. The focus is on: Pathogens: from the high-priority
Dear All: Three brief items for you today. First up: Perhaps like many of you, I’ve been wondering whether or not COVID-19 and bacterial resistance